Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Severe Immune Thrombocytopenia Possibly Elicited by the Anti-influenza Viral Agent Peramivir
Kayo Harada-ShiradoKazuhiko IkedaMiki FurukawaMasumi SukegawaHiroshi TakahashiAkiko Shichishima-NakamuraHiroshi OhkawaraHideyoshi NojiKinuyo KawabataShun-ichi SaitoHitoshi OhtoKazuei OgawaYasuchika Takeishi
Author information

2014 Volume 53 Issue 20 Pages 2369-2371


A 44-year-old man whose platelet count had been at the lower limit of the normal range for years visited the urgent care department of our hospital for treatment of a high fever and severe fatigue. The influenza A virus was detected, and the patient therefore received the intravenous antiviral agent, peramivir. One week later, he developed systemic petechial rashes. A peripheral blood examination showed a markedly decreased platelet count (3.0×109 cells/L), and the bone marrow findings were compatible with a diagnosis of immune thrombocytopenia (ITP). Furthermore, a drug-induced lymphocyte-stimulating test was positive for peramivir. The thrombocytopenia slowly responded to treatment with oral prednisolone. This case suggests that neuraminidase inhibitors, including peramivir, can elicit or worsen ITP.

Content from these authors
© 2014 by The Japanese Society of Internal Medicine
Previous article Next article